Roche reported that giredestrant missed the primary progression‑free survival endpoint in the PersevERA Phase 3 trial as a first‑line therapy for ER‑positive, HER2‑negative advanced breast cancer. The company and independent analysts described the miss as a material setback for the oral SERD program in that treatment setting and noted it will force a re‑evaluation of clinical positioning. Roche’s failure in PersevERA contrasts with prior positive signals in adjuvant and later‑line settings, complicating development strategy for oral SERDs and raising questions about the mechanism’s limits in first‑line disease. Competitors and investors immediately re‑priced competing oral SERD programs and related assets. Roche indicated it will review the full dataset to explore subgroups and secondary endpoints and decide next regulatory and development steps.